Last 40 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -9.30 | — | — | — | — | — | — | — | 14.23 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1608.41 | 1664.09 | — | 845.23 | 24.03 | — | 2217.88 | 2765.44 | 6.36 | — | 15.86 | 8.90 | 132682.46 |
| — | — | — | -69.4% | +277.6% | — | +13886.1% | +30984.9% | -100.0% | — | -99.8% | -99.9% | +117759.4% | |
| P/B Ratio | 2.81 | 3.09 | 2.48 | 1.60 | 1.74 | 2.06 | 2.32 | 2.68 | 2.70 | 2.09 | 2.44 | 1.92 | 1.70 |
| — | +49.6% | +6.9% | -40.2% | -35.6% | -1.0% | -5.3% | +39.4% | +59.3% | -20.0% | +8.5% | -11.0% | -29.9% | |
| P/FCF | — | — | — | — | — | — | — | 12.78 | — | — | — | 154.99 | — |
| — | — | — | — | — | — | — | -91.8% | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | 16.58 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | 17.75 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
CRISPR Therapeutics AG's operating margin was -14854.8% in Q3 2025. The trailing four-quarter average of -10732.7% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -2642.3% | -7177.1% | — | -6548.4% | 100.0% | — | -10920.5% | -10177.6% | 90.0% | — | 36.2% | 57.8% | -113616.7% |
| — | — | — | +35.7% | +11.1% | — | -30238.6% | -17705.8% | +100.1% | — | +100.2% | +100.3% | -11910.7% | |
| Operating Margin | -18933.6% | -14854.8% | — | -17158.8% | -184.5% | — | -29257.3% | -27894.2% | 34.8% | — | -136.0% | -64.5% | -2192350.0% |
| — | — | — | +38.5% | -630.4% | — | -21407.5% | -43155.6% | +100.0% | — | +99.9% | +99.9% | -193994.1% | |
| Net Margin | -16569.8% | -11973.1% | — | -15722.1% | -106.6% | — | -24450.3% | -23133.1% | 44.7% | — | -111.1% | -53.1% | -1842916.7% |
| — | — | — | +32.0% | -338.6% | — | -21916.0% | -43494.0% | +100.0% | — | +99.9% | +99.9% | -168198.2% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -30.2% | -5.9% | -11.8% | -7.2% | -1.9% | -4.4% | -6.2% | -5.9% | 4.9% | -6.3% | -4.2% | -2.8% | -5.8% |
| — | -33.9% | -89.4% | -23.0% | -138.9% | +30.7% | -46.8% | -106.6% | +185.7% | +26.7% | +50.6% | +63.1% | -0.4% | |
| ROA | -25.8% | -5.0% | -9.9% | -6.2% | -1.7% | -3.7% | -5.3% | -5.0% | 4.1% | -5.2% | -3.5% | -2.4% | -4.8% |
| — | -33.2% | -87.9% | -23.5% | -140.1% | +28.6% | -51.1% | -111.2% | +186.0% | +27.8% | +52.3% | +64.6% | +5.1% | |
| ROIC | -27.4% | -5.5% | -9.7% | -6.1% | -2.6% | -4.5% | -6.8% | -6.3% | 3.3% | -6.5% | -4.2% | -2.6% | -5.5% |
| — | -23.2% | -42.9% | +3.8% | -177.5% | +30.7% | -60.2% | -138.5% | +160.2% | +16.0% | +43.9% | +64.9% | +14.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 25.1% YoY to 16.22x, tightening the short-term liquidity position.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.11 | 0.11 | 0.13 | 0.12 | 0.12 | 0.12 | 0.12 | 0.11 | 0.13 | 0.14 | 0.14 | 0.13 | 0.13 |
| — | -6.1% | +7.8% | +6.4% | -8.7% | -16.1% | -13.5% | -13.0% | -2.6% | +12.8% | +16.4% | +21.7% | +38.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | 3.20 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.32 | 16.22 | 16.61 | 15.64 | 22.07 | 21.64 | 15.73 | 17.81 | 17.54 | 15.83 | 14.00 | 13.00 | 15.30 |
| — | -25.1% | +5.6% | -12.2% | +25.8% | +36.8% | +12.4% | +37.1% | +14.6% | +23.6% | -20.3% | -34.6% | -24.1% | |
| Quick Ratio | 13.32 | 16.22 | 16.61 | 15.64 | 22.07 | 21.64 | 15.73 | 17.81 | 17.54 | 15.83 | 14.00 | 13.00 | 15.30 |
| — | -25.1% | +5.6% | -12.2% | +25.8% | +36.8% | +12.4% | +37.1% | +14.6% | +23.6% | -20.3% | -34.6% | -24.1% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 40 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonCRISPR Therapeutics AG's current P/E is -9.3x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CRISPR Therapeutics AG's current operating margin is -18933.6%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CRISPR Therapeutics AG's business trajectory between earnings reports.